A spokesperson of Merck Sharp & Dohme announced that the company agreed to plead guilty to one count of misbranding Vioxx. The unit of Merck & Co., the second-largest U.S. drug maker, plead guilty to a criminal misdemeanor charge as part of a $950 million settlement of a U.S. government probe of its illegal marketing of the painkiller Vioxx.
After an Arkansas jury found that Johnson & Johnson (JNJ) company officials misled doctors and patients about the risks of one of their drugs, a judge ruled that JNJ must pay more than $1.1 billion in fines. The drug was an antipsychotic medication called Risperdal. The jury had concluded that J&J’s marketing of this particular drug violated both Medicare fraud laws and Arkansas’s deceptive trade practices statutes.
California Medical Billing Company Resolves Allegations of False Claims to Federal Health Care Programs
The Justice Department announced today that Janzen, Johnston & Rockwell Emergency Medicine Management Services Inc. (JJ&R), who handles billing services for physicians, hospitals and other health care providers, was accused of submitting false claims to Medicare and Louisiana’s Medicaid program and has agreed to settle and pay the United States $4.6 million.
Supreme Court Rules that Laws Limiting Marketing Efforts of Drug Manufacturers Are a Violation of Free Speech
On Thursday, the United States Supreme Court struck down a Vermont law that blocked drug manufacturers’ use of prescription drug information in marketing campaigns designed to sell new drugs to physicians. Although the law was designed to hold down health care costs and shield physicians from harassing marketing campaigns by preventing manufacturers from using prescription drug information to craft marketing campaigns,
Drug Lobbyists Spin Kickbacks Arising from Omnicare Whistleblower Litigation to be in the Public Interest
- December 15, 2010
Drug lobbyists, PhRMA and BIO have been trying to sell the public on claims that kickbacks involved in the Omnicare Whistleblower Litigation, in which Omnicare, a prominent pharmacy benefit manager, allegedly accepted bribes from most top drug companies in return for pushing expensive medicines over cheaper alternatives, offered rebates to Omnicare,
Teva Pharmaceuticals, the Israeli generic pharmaceutical manufacturer, has settled, for $169 million, claims pending against it in Texas, California and Florida related to overpricing of its pharmaceutical products. Under the scheme, Teva had provided the drugs at issue to private pharmacies including Walgreens and Wal-Mart at steeply discounted rates, but reported higher prices to the states’
Elan Corporation, plc, of Dublin, Ireland has agreed to settle claims related to the marketing of Zonegran, an anti-epileptic drug for which it sold the rights to a Japanese company in 2004. In January of 2006, Elan admitted that the the DOJ and the Department of Health and Human Services were looking into its marketing practices,
The United States Attorney’s Office for the District of Massachusetts announced the settlement of multiple false claims act cases against Omnicare, Inc. of Covington, Kentucky, for $98 million for soliciting and receiving multiple kickbacks. The first scheme involved Johnson and Johnson and kickbacks for recommending that physicians prescribe Risperdal, a J&J antipsychotic drug,
Fourteen states and the District of Columbia have filed a false claims act suit against Amgen, accusing the biotech company of using kickbacks to sell its anemia drug Aranesp (darbepoetin alfa).
In court papers filed Oct. 30 in U.S. District Court for the District of Massachusetts, the states and D.C.
AstraZeneca PLC announced that it has reached an agreement “in principle” to pay $520 million settle an investigation by the United States Department of Justice into the company’s marketing of schizophrenia drug Seroquel.
The U.S. Attorney’s Office in Philadelphia has been leading an investigation into AstraZeneca’s marketing of Seroquel,